As a potent inhibitor of NF-κB 23, Oridonin was suggested to be of therapeutic importance for the treatment of AD pathology, not only by blocking inflammatory processes but also by directly inhibiting the production of Aβ peptides 28. This evidence concerns the gene NFKB1 and Alzheimer disease.